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( 57 ) ABSTRACT 
A method and device for using insulin sensitivity values to 
estimate the distribution of future insulin sensitivity values 
for a given patient based on dimensional relationships 
between current , prior and delta insulin sensitivity values , 
and observed future insulin sensitivity values for similar 
patients or subjects , or based on an individual patient or 
subject's historical values . 
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ESTIMATION OF FUTURE INSULIN SUMMARY 
SENSITIVITY DISTRIBUTIONS 
In accordance with one aspect of the present invention , 
CROSS REFERENCE there is provided a method for controlling the blood glucose 
5 levels of a patient including the steps of : 
This application claims the benefit of the filing date of a ) measuring the blood glucose level of the patient ; 
U.S. Provisional Patent Application Ser . No. 62 / 662,992 , b ) determining the current insulin sensitivity of the 
filed Apr. 26 , 2018 , which is hereby incorporated by refer- patient ; 
ence in its entirety . c ) estimating with a multi - dimensional model the adjust 
ment needed to obtain a blood glucose level between a 
FIELD desired lower and upper confidence interval after adminis 
tration of the estimated adjustment to the patient ; 
The present invention relates to a glycaemic control d ) administering the estimated adjustment to the patient ; 
device and methods for insulin sensitivity prediction and and 
control . e ) repeating steps a ) through d ) until a desired state of 
health is achieved . 
BACKGROUND In accordance with another aspect of the present disclo 
sure , there is provided a device for controlling the blood Insulin sensitivity ( SI ) is a main determinant of blood 20 glucose levels of a patient , including : 
glucose level in all humans and animals with metabolism . In a processor programmed to forecast with a multi - dimen 
diabetes , insulin resistance and hyperglycemic hospital sional model based on the current insulin sensitivity and the patients , deranged blood glucose levels are treated with % change in insulin sensitivity from a prior insulin sensi 
insulin and / or nutrition and / or activity . Activity affects SI tivity value , the adjustment needed to obtain a blood glucose 
levels and need for nutrition , and insulin and nutrition act in 25 level between a desired lower and upper confidence interval 
balance to yield outcome glycemia . Controlling blood glu after administration of the estimated adjustment to the cose levels can be very difficult as SI can vary substantially , patient ; 
particularly in hospitalized patients . a memory ; Insulin therapy for glycaemic control ( GC ) in critically ill a data input ; and patients improves outcomes by reducing hyperglycaemia 30 a display . and glycaemic variability , which are both associated with In accordance with another aspect of the present disclo increased morbidity and mortality . However , results have sure , there is provided a device for controlling the blood proven difficult to repeat or achieve safely . 
Critically ill patients in intensive care units ( ICUS ) often glucose levels of a patient , including : a processor pro experience abnormally elevated blood glucose concentra- 35 grammed to forecast with a multi - dimensional model based 
tions ( hyperglycaemia ) , as a stress response to illness and on the current SI and the % change in SI from a prior SI 
injury . Hyperglycaemia , glycaemic variability , and hypogly value , the insulin / nutritional adjustment needed to obtain a 
caemia are all independently associated with increased mor blood glucose level between upper and lower CIs ( e.g. , the 
bidity and mortality . Glycaemic control using insulin 5 % and 95 % CI ) after administration of the forecasted 
therapy has shown beneficial outcomes , reducing organ 40 insulin / nutritional adjustment to a patient ; a memory ; a data 
failure and costs but with increased risk of hypoglycaemia input ; and a display . 
with tight control . These and other aspects of the present disclosure will 
GC has been hard to achieve both safely and effectively . become apparent upon a review of the following detailed 
Fixed or ad hoc protocols are still typically used in hospitals , description and the claims appended thereto . 
but fail to capture and fully account for patient variability 45 
impacting performance and safety . This issue has led to the BRIEF DESCRIPTION OF THE DRAWINGS 
emergence of more complex , model - based GC protocols . 
STAR ( Stochastic TARgeted ) is a clinically - validated FIG . 1 shows the input values to calculate SI ( t = 2 ) in 
model - based GC framework , capable of adapting treatment accordance with the Example of the present invention ; 
to patient - specific insulin requirements while managing the 50 FIG . 2 shows the calculation of SI ( t = 2 ) using the physi 
risk of hypoglycaemia . ological model in accordance with an embodiment of the 
The stochastic model currently used by STAR forecasts present invention ; 
future SI ( SIn + 1 ) distributions based on the identified cur- FIG . 3 shows the forecasted SI at a future time at different 
rent SI value ( SIn ) . A Markov process is used , where % delta SI values using stochastic model in accordance with 
outcome Sin + 1 only depends on input SIn . This allows risk 55 an embodiment of the present invention ; 
based rather than target based dosing . However , STAR has FIG . 4 shows the forecasted bands ( 90 % CI ) of SI at 
been found to be overly conservative and there is a need for various future times in accordance with an embodiment of 
an approach using more data inputs with a noncomplex the present invention ; 
model to more rapidly bring insulin / glucose levels into a FIG . 5 shows the prediction of BG traces ( 5th and 95th 
stable , safe level . 60 percentile ) for different combination of insulin and nutrition 
Thus , more optimal treatment could be provided if there inputs in accordance with the Example of the present 
was a means to predict future distributions of SI as likeli- invention ; 
hoods . From these distributions , explicit quantifiable risks FIG . 6 shows the input values to calculate SI ( t = 3 ) in 
could be created to assess an individual's health state and / or accordance with an embodiment of the present invention ; 
adjust treatment . These predictions could be patient - specific 65 FIG . 7 shows the calculation of SI ( t = 3 ) using the physi 
or more generally related to a cohort or similar or otherwise ological model in accordance with an embodiment of the 
grouped individuals . present invention ; and 
10 
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FIG . 8 shows BG in a desired range with inputs of insulin Equally with kernel density , this grouping is done math 
and nutrition over t = 0 to t = 10 ) in accordance with the ematically using a statistical distribution . Thus , the likeli 
Example of the present invention . hood of any input data set is calculated from the nearby sets 
of input parameters that are similar . From this calculation , 
DETAILED DESCRIPTION 5 the likelihood of occurrence can be calculated . 
According to an embodiment of a method to assess or 
A method for controlling the blood glucose level of a alarm for potential input errors in SI , the clinical data used patient includes the steps of : to evaluate SI , and / or other input data when an input has a ) measuring a blood glucose level and determining an ( clinically or otherwise selected ) very low probability of insulin sensitivity of the patient ; occurrence ( below any set threshold ) and thus lies in a b ) measuring , subsequent to step a ) , the blood glucose region of low or no existing data . Such errors arise from a level and determining the current insulin sensitivity of the range of either data input errors or failures in care , including patient ; errors in clinical data , data input errors , failed pump , false c ) estimating with a multi - dimensional model , comprising measurement , or failure to eat a meal , glucose or any other delta SI , the adjustment needed to obtain a blood glucose 15 sensor error or any other incorrect input due to error or level between a desired lower and upper confidence interval misuse . 
after administration of the estimated adjustment to the According to an embodiment , as an example , the model at patient ; any given point could be adjusted to within a specified d ) administering the estimated adjustment to the patient ; range , e.g. , a target of 4.5 mmole / L . The target can be set as and 10 to 90 % or 5 to 95 % probability and also a lower limit of e ) repeating steps b ) through d ) until a desired state of the next point to be below 3. The model shows the risk for health is achieved . a certain amount of insulin and nutrition . An example can be The multi - dimensional data base can be constructed seen in FIG . 3 where the prediction shows what could according to the following procedure . Accumulation of happen with various insulin and nutrition inputs . relevant physiological data used or used to derive patient 25 Certain identified levels of blood glucose can correspond specific physiological metrics ( e.g. , SI from glucose , insulin , to what is light , mild , moderate or severe hypoglycemia . The nutrition data ; or pulse pressure variation from arterial model would then give results of what is the risk of landing pressure waveforms ; or HRV heart rate variability from in the mild to severe range . In general a clinician would pick heart rate ECG data ) calculated from data directly or via a input that is predicted to avoid hypoglycemia . In practical model from a plurality of patients . This data can be stored 30 use in ICU this model has reduced hypoglycemia to a very for each patient over time and can then be processed or low level compared to ICU not using the model . organized in N - dimensional groups based on what sets of A primary and exemplar embodiment relates to a multi inputs and resulting output ( s ) are desired . dimensional model developed on the ability to predict more Using measured data from a large multinational cohort , SI accurate future SI distributions , using both current SI and its values may be obtained from a model , such as auto regres- 35 percentage change from the prior value . In an embodiment , sive or neural network . The model includes the relationships SI is obtained from 70,000 hours of clinical data to create a of current SI , delta SI , and the adjustment level to future SI . multi - dimensional stochastic model . For any individual , a history or trajectory of SI values can An embodiment of a multi - dimensional model character be collected prospectively or retrospectively . These trajec ises patient specific metabolic variability and patient specific tories of values can be used to create relationships between 40 response to insulin , allowing more optimal insulin dosing to current or recent Si ( n ) , its changes and other relevant input increase performance and safety . This method expands the values to predict a future SI ( n + dt ) , for example , where dt = 30 prior 2D stochastic approach by adding the most recent minutes to 48 hours or more . change in SI , as an input parameter for forward prediction In an embodiment , the multi - dimensional model is based of outcome SIn + 1 . The multi - dimensional model of the upon clinical input data . Suitable input includes the follow- 45 present invention predicts future SIn + 1 based on current SIM ing : physiological measurements ; severity of health condi and the percentage change in SI from SIM - 1 to SI ... tion scores based on measurements and / or diagnoses and / or The ICING ( Intensive Control Insulin - Nutrition - Glucose ) treatments ; or anthropomorphic metrics , including sex , size , physiological model describing glucose - insulin dynamics is weight , height , and the like ; or any metric derived from one defined as : or more thereof . Suitable input also includes the following : 50 
current SI and prior SI or % delta SI ; current and prior blood 
glucose levels ; current and prior HR , HRV or other metrics Q ( 1 ) P ( 1 ) + EGP - CNS ( 1 ) 
accounting for activity or exercise ; current diagnosis in ? = -PG . G ( 1 ) - SI.G ( ) 1 + QGQ ( t ) VG 
hospital ) or severity score ( Apache II , SAPS , TISS , SOFA or 
similar diagnostic or severity score ) ; predicted future inter- 55 I ( 1 ) ( I = = nk · I ( t ) - 1L - n / ( ( 1 ) - Q ( t ) ) + + ( 1 - XL ) ventions of insulin and / or nutrition and / or exercise or other 1 + aj · I ( 1 ) V Vi 
metrics accounting for activity or exercise ; or any metric Q ( 1 ) ( 3 ) 
derived from one or more thereof . These inputs allow more Q = n ; ( I ( t ) - Q ( 0 ) ) - no 1 + QgQ ( t ) personalized predictions of glucose levels and more aggres 
sive treatment with insulin and / or nutrition without safety 60 
issues . The clinical input data can be derived from an Where G ( t ) is the blood glucose level ( mmol / L ) , I ( t ) is the 
individual or group or sub - cohort of individuals , including plasma insulin concentration ( mU / L ) , Q ( t ) is the interstitial 
male groups , or female groups . insulin concentration ( mU / L ) , P ( t ) is the glucose appearance 
According to an embodiment , all possible sets of input in plasma from enteral and parenteral dextrose intake 
data are contemplated . These sets are grouped into a set of 65 ( mmol / min ) , and SI is insulin sensitivity ( L / mU / min ) . 
vertices in that n - space , the number is known as well as the Model - based insulin sensitivity ( SI ) is patient - specific 
total number of possible input data sets within the database . and time varying , characterizing patient - specific glycaemic 
+ 
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system response to glucose and insulin administration . SI is An insulin administration where this event is less than 10 % 
identified hourly from clinical BG , and insulin and nutrition likely is considered as safe . This is done by taking marginal 
input data , using an integral - based fitting method . distributions where the insulin administration is held con 
The model - based glycaemic controller is a clinically stant and identifying where to overlap of the distribution and 
validated model which identifies current patient - specific 5 the region of safe BG levels are attained . Integrating the 
insulin sensitivity using metabolic data , and forecasts likely distribution in the safe region provides a confidence level of 
blood glucose ( BG ) outcomes for a given insulin and patient safety for a given dose . Finding a dose which meets 
nutritional adjustment by assessing inter- and intra - patient these considerations is a solution to balancing the moving 
variability . However , the model's predictions and the patient the patient to a desired BG level and maintaining a confi 
outcome may differ , and the difference is a random variable . 10 dence the patient will not encounter undesirable affects . The disclosure will be further illustrated with reference to This is not surprising , as the typical use of the data is to 
administer insulin and nutrition so as to affect the expected the following specific examples . It is understood that these examples are given by way of illustration and are not meant result , so it is likely that the actual result will stray from the to limit the disclosure or the claims to follow . expected value . Clearly to have an expected result there 
needs to be evidence , in terms of past clinical results , to base Example Case Study 
the expected effects . The variability is and has been captured 
as a multi - dimensional probability distribution gathered A patient has been under STAR for a couple hours from a large population of patient data . The distribution of because of hyperglycaemia . past data can be applied as a stochastic model of affects from Nutrition , insulin , previous BG levels and previous iden 
the administration of insulin and nutrition . The distribution tified SI levels have been recorded and are thus known . It is 
of past data can be used to determine the expected result , but now 2 hours after the beginning of STAR ( t = 2 ) , and it is time additionally , the distribution of results from an administra to calculate the new treatment . 
tion of insulin and nutrition are established . Using the Step 1 ( SI Identification ) : distribution it is possible to predict the range of likely future A new measure of BG is taken : BG ( t = 2 ) = 8.223 mmol / L . variation of SI over the following hours ( e.g. , 1 to 3 ) after Nutrition rate ( 6.7 g / hr ) and insulin rate ( 6 U / hr ) over the an insulin and nutritional adjustment . This can be used to the last period are known . positively affect patient safety , as adverse responses can be Only current SI is unknown at this point but can be greatly reduced . determined using integral based methods as it is the only In the following the SI levels are indexed based upon the 30 unknown parameter . 
administration of insulin and nutrition . SI is determined by Solving the system of equations from the physiological 
solving a differential equation that utilizes parameters model for SI over the last hour as shown in FIG . 1 gives : 
obtained from clinical data . One standard method of solving 
the differential equation is the so - called integral based SI ( t = 2 ) = 3.5951e - 4 L / mU / min . 
method , a forward differencing scheme , though other Step 2 ( SI Previous Variability ) : 
approaches are available . Hence SI , is the initial insulin This new SI value ( see FIG . 2 ) already gives an idea of the 
sensitivity value and SI ,, is the nth administration . Inputs to previous patient - specific metabolic variability ( over the last 
the methods utilize the current value ( SIN ) and its percentage two hours ) . Another metric can be used to describe this 
change from prior intervention ( % ASI , ) . This range is used variability : 
to compute the optimal insulin and nutritional adjustment 
resulting in BG outcomes that best overlap a targeted band 
( e.g. , 4.4 to 6.6 mmol / L ) while minimizing risks of hypo Sin - Sin - 1 % ASIn = 100 x glycaemic events , ensuring a maximum 5 % risk of predicted 
BG outcomes below a lower limit ( e.g. , 4.4 mmol / L ) . An 
administration where the overlap is at least 90 % is consid 
ered clinically safe . It represents the hour - to - hour percentage SI variability ( the % change from the previous to current SI value ) . An embodiment of a step - by - step approach is detailed 
below : Acurrent model - based SI , parameter is identified for SI ( t = 1 ) = 3.9745e - 4 
the patient using available clinical data ( e.g. , insulin rates , 
nutrition rates , and current blood glucose level ( BGW ) ) . SI ( t = 2 ) = 3.5951e - 4 
Optionally , determine the prior percentage change in SI in 
accordance with the formula % ASI ( t = 2 ) = - 9.55 % 
SI decreased of 9.55 % from its previous value ( the patient 
is quite stable , but slightly more resistant to insulin than the 
Sin – Sin - 1 previous hour ) . 100 x Step 3 ( Identification Future SI Variability ) : 
Now STAR knows the past / current patient - specific state , 
when the prior SI parameter , SI.1-1 , is available . It is under it will determine how likely it will change in the future . 
stood that the change can be ascertained once an adminis Thus , it will use the stochastic model ( constructed on 
tration has occurred and clinical measurements have been 60 population data ) with the identified current SI and % ASI as 
attained . inputs , to predict the 90 % CI range of likely future SI ( t = 3 ) 
Calculate , utilizing the stochastic model , the 90 % CI of value . In other words , a range within which we are confident 
likely variation of SI , represented as ( SIn + i ) , over each of the at 90 % that the future SI ( t = 3 ) will fall in , based on the 
next 1 , 2 , and 3 hours based on SI , and % ASI ,. previous patient - specific SI evolution . A 
consideration is given to the fact that a patient's response to 65 Given % ASI ( t = 2 ) = - 9.55 % and SI ( t = 2 ) = 3.5951e - 4 , the 
an insulin administration might cause the BG to become too resulting 90 % CI range for predicted SI ( t = 3 ) is : 
high or too low and put a patient into a high risk situation . [ 2.4390e - 4,5.4042e - 4 ] 
35 
40 
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This step can also be done to predict likely future SI in 2 predicted and very close to the lower limit of the safe target 
or 3 hours : band . This explains the following 0 U / h of insulin and 100 % 
nutrition input treatment suggestion . The predicted BG ( blue 90 % CI range for SI ( t = 4 ) : [ 2.4380e - 4,5.6128e - 4 ] line ) will never be lower than the black dashed line unless 
5 treatment - independent ( 0 U / hr and full nutrition target ) . 90 % CI range for SI ( t = 5 ) : [ 2.4548e - 4,5.8596e - 4 ] Discussion of main results . Estimating changes in insulin 
Generally wider bands represent longer prediction times sensitivity underpins the ability of STAR to respond in a 
( more likely to have higher variability over longer periods of patient - specific manner to potential future changes in patient 
time ) . glycaemic control requirements , resulting in safe and effec 
Step 4 ( Treatment Computation ) : 10 tive control strategies . If the distributions of forecast likely 
Based on this assessment of likely evolution of patient SI changes are narrower , then control can be further 
variability ( future SI variability / evolution ) , STAR will use improved , with tighter control in more stable patients , and 
the physiological / mathematical model again , but slightly better avoidance of hypo - glycaemia in patients that exhibit 
differently . high glycaemic variability . 
This time , knowing SI range ( SI is not unknown any- 15 The current invention is more patient - specific , and better 
more ) , we want to determine what intervention ( insulin and predicts likely BG outcomes as compared to the prior model . 
nutrition ) to give to the patient so the resulting predicted BG These results translate into more aggressive insulin dosing 
range ( because this is based on predicted values of SI ) is where patients are more stable and SI outcomes are more 
within the clinically specified safe target range . Thus : certain , and less aggressive , lower insulin doses in patients 
SI is known ( 5th and 95th percentiles of future SI ) 20 who are more variable . Greater patient - specificity also 
Nutrition and Insulin rates are now variables reduces risk for more variable patients . The current inven 
BG is now the only unknown of the equations , which can tion leads to tighter and less variable control with greater 
be determined solving the sets of equations . safety from hypo - glycaemia , and thus improved outcomes . 
Note : There exists a discrete number of insulin / nutrition Although various embodiments have been depicted and 
combination due to clinical settings constraints ( i.e. , Insulin 25 described in detail herein , it will be apparent to those skilled 
rate can range from 0 to 9 U / hr with 0.5 U / hr increment steps in the relevant art that various modifications , additions , 
with maximum 2 U / hr increment , nutrition can vary from 30 substitutions , and the like can be made without departing 
to 100 % of the total original goal feed with 5 % increment from the spirit of the disclosure and these are therefore 
steps and maximum of 30 % change ) . considered to be within the scope of the disclosure as defined 
STAR will thus loop through all the possible insulin / 30 in the claims which follow . 
nutrition combinations and find the optimal solution : adjust 
ing the 5th percentile of predicted BG to 4.4 mmol / L while What is claimed is : 
maximizing overlapping with the target band . This ensures 1. A method for controlling the blood glucose level of a 
a maximum risk of 5 % of hypoglycaemia . STAR always aim patient comprising the steps of : 
to maximize nutrition . a ) measuring a blood glucose level and determining an 
FIG . 5 shows prediction of BG traces ( 5th and 95th insulin sensitivity of the patient ; 
percentiles given the 95th and 5th SI percentiles values ) for b ) measuring , subsequent to step a ) , the blood glucose 
different combination of insulin and nutrition inputs . The level and determining the current insulin sensitivity of 
green line ( no insulin and full nutrition ) results in higher the patient ; 
predicted BG , whereas the blue line ( higher insulin and 40 c ) estimating with a multi - dimensional model , comprising 
lower nutrition rates ) results in lower predicted BG values . delta Si , an adjustment needed to obtain a blood 
The blue option represented here is the one calculated by glucose level between a desired lower and upper con 
STAR ( within the possible insulin / nutrition combinations fidence interval after administration of the adjustment 
according to ICU specifications ) . to the patient ; 
This can be done for the 2 and 3 hours prediction . d ) administering the adjustment to the patient ; and 
Step 5 ( Treatment selection ) : e ) repeating steps b ) through d ) until a desired state of 
Now that STAR calculated the best treatment it will health is achieved . 
suggest the determined combination to the nurse . STAR can 2. The method of claim 1 , wherein the multi - dimensional 
offer 2 and / or 3 hourly treatments if and only if an existing model comprises clinical input data comprising current SI , 
solution met the safety criteria ( and if not restricted by other 50 prior SI , % delta SI , current blood glucose level and prior 
constraints ) . blood glucose level . 
Nurses are thus able to choose between the 1-3 hourly 3. The method of claim 2 , wherein the clinical input data 
treatment ( if available ) , that seems best to match their is from an individual or group or sub - cohort of individuals . 
clinical judgement . 4. The method of claim 2 , wherein the multi - dimensional 
In this case study , only the 1 - hour treatment is possible 55 model provides a risk assessment based upon a given insulin 
( because current BG is outside the target range ) . The only or nutrition input . 
suggested option by STAR thus corresponds to : 8 U / h of 5. The method of claim 4 , wherein the assessment is of 
insulin ( increase of 2 U / h ) 4.1 g / h of nutrition ( decrease of light , mild , moderate or severe hypoglycemia defined by 
30 % of max cal . Intake ) The new measured BG ( t = 3 ) is specific blood glucose levels . 
within the predicted band by STAR . 6. The method of claim wherein a likelihood is assessed 
The new corresponding identified SI ( t = 3 ) value is within of any set of input data occurring given the number of points 
the predicted SI range . grouped within the same set of input data and the total 
Simulation Overview : The full simulation results are number of input data point groups in the entire set of 
shown in FIG . 8 , with the corresponding BG prediction associations . 
range for each treatment selected . 7. The method of claim 2 , wherein the multi - dimensional 
As shown in top panel of FIG . 8 , at t = 3 , the 3 - hour model is used to assess for potential input errors in SI , the 
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when an input has very low probability of occurrence and a processor programmed to forecast with a multi - dimen 
thus lies in a region of low or no existing data . sional model based on a current insulin sensitivity and 
8. The method of claim 1 , wherein the adjustment com a % change in insulin sensitivity from a prior insulin 
prises insulin administration , nutrition , exercise , or combi sensitivity value , an adjustment needed to obtain a 
nations thereof . blood glucose level between a desired lower and upper confidence interval after administration of the adjust 9. The method of claim 1 , wherein the desired lower and ment to the patient ; upper confidence interval comprises 5 % and 95 % or 10 % a memory ; 
and 90 % , respectively . a data input ; and 
10. The method of claim 1 , wherein the multi - dimensional a display 
model is based on the determined current insulin sensitivity 12. The device of claim 11 , wherein the processor is 
and a % change in insulin sensitivity from a prior insulin programmed to forecast with a multi - dimensional model 
sensitivity value , and the adjustment comprises an insulin / based on the current insulin sensitivity and the % change in 
nutritional adjustment needed to obtain a blood glucose level insulin sensitivity from a prior insulin sensitivity value , an 
between a desired lower and upper confidence interval after insulin / nutritional adjustment needed to obtain a blood glu 
administration of the estimated insulin / nutritional adjust cose level between the 5 % and 95 % confidence interval after 
ment to the patient . administration of the insulin / nutritional adjustment to a 
11. A device for controlling the blood glucose levels of a patient . 
patient , comprising : 
10 
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